Solutions

Respiratory Panels

4 actionable pathogen targets

Faster Innovation

The only diagnostics center built from the ground up by a robotics company, we combine automation with proprietary assay development to innovate molecular diagnostics faster than any other provider

Test & Treat More Patients

Rapid test results allow a larger number of patients to be tested and treated. Overall cost-of-care reduced more than $8,000 per patient relative to batch testing

Operational Savings

End-to-end diagnostics automation means less staff, operational, & logistical resource spend for hospitals, with annual operational cost savings of $12M

Maximized Resources

Reduce in-hospital foot traffic & resource use

Syndromic PCR Testing for Respiratory Infections

Improving patient care at reduced costs with clear diagnosis
Download White Paper

Respiratory Panel Offerings

Target up to 4 pathogens at once with 99% of results in < 24 hours

Influenza A

Sensitivity (PPA)=97.5% (95% CI 91.3 – 99.3) Specificity (NPA)=100% (95% CI 95.4 - 100)

Influenza B

Sensitivity (PPA)=95% (95% CI 87.8 – 98) Specificity (NPA)=100% (95% CI 95.4 - 100)

SARS-CoV-2

Sensitivity (PPA)=96.25% (95% CI 89.6 – 98.7) Specificity (NPA)=100% (95% CI 95.4 - 100)

Respiratory Syncytial Virus

Sensitivity (PPA)=95% (95% CI 87.8 – 98) Specificity (NPA)=100% (95% CI 95.4 - 100)

*Data from PRL DC lab (PRL 167 VAL: PRL DC cRP ITM Assay Validation, Rev 1.0. 12/28/21). Tests run in each PRL laboratory are independently developed and validated at their respective facility; performance of tests may vary.

Improve Patient Outcomes

Turnkey, high touch service includes LIS integration to help you help patients

Trusted Partner

Partner of choice for routine and ambulatory testing

Concise Panel

Fixed panel composition with 4 targets: SARS-CoV-2, Influenza A, Influenza B, RSV

Comprehensive Panel (Coming Soon!)

Flexible panel composition with 21 targets: 4 Bacteria, 17 Viruses

Supports Antimicrobial and Antibiotic Stewardship

13% reduction in antibiotic therapy duration. ICU patients had a 10% increase in survival rate compared to batch testing (Martinez, et al. Clinical Virology Symposium. 2016)

FAQs

What pathogens are targeted in the concise & comprehensive PRL respiratory panels?
What sample types are accepted for the Concise Respiratory Panel?
What is the sample stability for the Concise Respiratory Panel?
What is the sample volume required for the Concise Respiratory Panel?
What are the sample collection kits that can be used with the Concise Respiratory Panel?
What sample types are accepted for the Concise Respiratory Panel?
How accurate is the Concise Respiratory Panel?
What is the regulatory status of the Concise Respiratory Panel?
What is the turnaround time for the test?
What is the CPT billing code for the Concise Respiratory Panel?
What are the panel part numbers for ordering?
What is the test methodology for the respiratory panels?
Is PRL CLIA certified?
Where can I find PRL?
Which states can submit samples to our Rockville, MD CLIA lab?

The product contains a test for COVID-19, which has not been FDA cleared or approved. For our testing in our Maryland and NY labs, the COVID-19 test has been authorized by clinical laboratory authorities in the State of New York and the State of Maryland for use by the authorized laboratory in each such state. For our California lab, an EUA for the COVID-19 test was submitted to the FDA on August 12, 2021 and is under review.

PRL provides nationwide, industrial-scale COVID-19 variant detection, pool testing, and gold-standard PCR testing.

© 2022 PRL. All rights reserved.
PRL NYC
Pandemic Response Lab 45-18 Ct Square West Long Island City, NY 11101 CLIA# 33D2196459 CAP# 9038601
PRL DC
Pandemic Response Lab 9605 Medical Center Dr. Suite 220 Rockville, MD 20850 CLIA# 21D2215498 CAP# 9075286
PRL OC
131 Innovation Drive, Suite 150 Irvine, CA 92617 CLIA# 05D2230382
Customer Support
cxsupport@reopenlabs.com (888) 672-3144
© 2022 PRL. All rights reserved.